Abbott says GLP-1s could boost CGM use, new report claims Philips withheld CPAP problems from FDA

Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here’s what you need to know for today, September 29, 2023. Check out the show notes for links to the stories we discuss today at MassDevice.com/podcast. Inspira is set to unveil its new line of cardio-pulmonary bypass devices soon. Fast Five hosts Sean Whooley and Danielle Kirsh discuss which devices it is planning to unveil and what they do. Satio was awarded a $3.5 million contract to develop at-home transdermal drug delivery devices. Hear more about what the transdermal device is and what the contract will allow the company to do. The FDA has granted an investigational device exemption to EnCompass for its cerebral embolic protection system in TAVR procedures. Whooley explains how the device works and what some of the use data with the device has shown.  A new ProPublica and Pittsburgh Post-Gazette report has claimed that Philips reportedly withheld CPAP problems from the FDA for years. The Fast Five hosts provide some of the details from the ProPublica report, including Philips' reaction to the report.  Abbott has come out with its own data about how GLP-1 drugs could affect its continuous glucose monitors. The company thinks the drugs could actually accelerate its FreeStyle Libre usage. Whooley details what Abbott uncovered in the data and what analysts think.